RSV Prophylaxis (Infant) — MRCPCH AKP MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — No infant RSV prophylaxis is indicated
The correct answer is A. In the UK, the main RSV prevention strategy for infants is maternal vaccination during pregnancy. Monoclonal antibodies are offered selectively, including to infants born before 32 weeks’ gestation and to infants or young children with specified conditions conferring high risk of severe RSV disease. A healthy term infant does not become eligible solely because the mother was unvaccinated. Palivizumab is not routine prophylaxis and is a fallback only for eligible high-risk infants when long-acting monoclonal antibodies are unavailable. RSV vaccine is not given to young infants. If this infant were eligible for nirsevimab, the licensed weight-based dose would be 50 mg once because the weight is below 5 kg; however, there is no UK programme indication here.
Reference: UK Health Security Agency. RSV vaccination of pregnant women for infant protection: information for healthcare practitioners, section “Monoclonal antibody immunisation for high-risk infants”. Updated 3 June 2026. https://www.gov.uk/government/publications/respiratory-syncytial-virus-rsv-programme-information-for-healthcare-professionals/rsv-vaccination-of-pregnant-women-for-infant-protection-information-for-healthcare-practitioners